MST-0312 / Mestag Therap - LARVOL DELTA

STARLYS: Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies (clinicaltrials.gov) - P1 | N=157 | Recruiting | Sponsor: Mestag Therapeutics Limited

New P1 trial • Breast Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Mestag Therapeutics…announced the dosing of the first patient in a Phase 1 clinical trial evaluating MST-0312 in patients with selected advanced solid tumors (GlobeNewswire) - "The first in human trial, named the STARLYS trial, is an adaptive, modular multi-part, multi-arm open-label study designed to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and anti-tumor activity of MST-0312 alone and in combination with pembrolizumab."

First-in-human • Trial status • Solid Tumor

MST-0312: Targeted LTBR agonist designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) for the treatment of solid tumors (AACR 2026) - "MST-0312 and its surrogate were well tolerated, with no evidence of systemic cytokine release or off-target toxicity.In summary, MST-0312 is a novel FAP-LTBR bispecific antibody which induces TLS & HEV formation in the tumor and drives the recruitment, education and activation of anti-tumor immune cells leading to potent anti-tumor responses. TLS & HEV induction represents an exciting new therapeutic class with potential as monotherapy and in combination."

First-in-human • Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAFs • CD4 • CD8